23-chromosome microarray embryo selection does not improve embryo quality in a given cycle of ovarian stimulation. Rather, it allows for the identification and selection of high quality, "competent" embryos for transfer. As such, Arizona Center for Fertility Studies believes it may dramatically improve the live birth rate per embryo transferred and brings us much closer to a time where single embryo transfers will be come standard.
While 23-chromosome microarray testing (as is also the case for FISH-PGD) markedly reduces the risk of numerical chromosomal birth defects such as Down's syndrome, it does not absolutely preclude their occurrence. In fact, the anticipated error rate could be ≤5%. Thus all women undergoing microarray or FISH egg/embryo selection and who seek absolute confirmation that numerical chromosomal birth defects will not occur should still undergo prenatal genetic testing in the 1st or 2nd trimester.
Book your first appointment and get your free copy of Dr. Jay S. Nemiro's groundbreaking book,